Mechanisms of effects of complement inhibition in murine collagen-induced arthritis

被引:67
作者
Banda, NK
Kraus, D
Vondracek, A
Huynh, LH
Bendele, A
Holers, VM
Arend, WP
机构
[1] Univ Colorado, Hlth Sci Ctr, Div Rheumatol, Denver, CO 80262 USA
[2] BolderPATH Inc, Boulder, CO USA
来源
ARTHRITIS AND RHEUMATISM | 2002年 / 46卷 / 11期
关键词
D O I
10.1002/art.10591
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To determine the mechanisms of amelioration of collagen-induced arthritis (CIA) in DBA/1J mice by inhibition of complement activation., Methods-Mice received 2 intradermal injections of bovine type 11 collagen (CII), on days 0 and 21. From day 21 (immediately after the second injection of CII) through day 35, mice received intraperitoneal injections of either phosphate buffered saline (PBS), a monoclonal mouse antibody to murine C5 (anti-C5 antibody), or the C3 convertase inhibitor Crry-Ig. Results. On days 30 and 32, the clinical disease activity score was lower in mice treated with anti-C5 antibody than in those treated with Crry-Ig. Histopathologic evidence of joint damage was 75% lower in the mice treated with anti-C5 antibody than in those treated with either PBS or Crry-Ig. Spleen cells from mice receiving either form of complement inhibition exhibited decreased CII-stimulated proliferation, whereas increased proliferative responses were exhibited by lymph node cells from mice treated with Crry-Ig. Treatment with anti-C5 antibody decreased production of IgG1 anticollagen antibody, while production of IgG2a antibody was inhibited by both complement inhibitory treatments. CII-stimulated spleen cells from anti-C5-treated mice produced lower levels of tumor necrosis factor alpha (TNFalpha) and interleukin-10 (IL-10) compared with those from mice treated with Crry-Ig. Lower steady-state messenger RNA (mRNA) levels for TNFalpha, interferon-gamma (IFNgamma), IL-18, and IL-6 were observed in the joints of anti-C5-treated mice, and for IFNgamma and IL-6 in mice receiving Crry-Ig, all in comparison with PBS-treated mice. However, mRNA levels for IL-1beta and TNFalpha were lower in. the joints after treatment with anti-C5 compared with Crry-Ig. Conclusion. These results indicate that inhibition of complement in CIA leads to decreased production of IgG2a antibody and suppressed CII-induced spleen cell proliferation. The greater inhibitory effects on CIA of anti-C5 antibody in comparison with Crry-Ig may be attributable primarily to decreased levels of IL-1beta and TNFa mRNA in the joints.
引用
收藏
页码:3065 / 3075
页数:11
相关论文
共 46 条
[1]  
BANERJEE S, 1989, J IMMUNOL, V142, P2237
[2]   Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice [J].
Bao, LH ;
Haas, M ;
Boackle, SA ;
Kraus, DM ;
Cunningham, PN ;
Park, P ;
Alexander, JJ ;
Anderson, RK ;
Culhane, K ;
Holers, VM ;
Quigg, RJ .
JOURNAL OF IMMUNOLOGY, 2002, 168 (07) :3601-3607
[3]  
Bendele AM, 2000, ARTHRITIS RHEUM-US, V43, P2648, DOI 10.1002/1529-0131(200012)43:12<2648::AID-ANR4>3.0.CO
[4]  
2-M
[5]  
De Bandt M, 2002, ARTHRITIS RHEUM-US, V46, P522, DOI 10.1002/art.10085
[6]  
Dreja H, 2000, ARTHRITIS RHEUM-US, V43, P1698, DOI 10.1002/1529-0131(200008)43:8<1698::AID-ANR5>3.0.CO
[7]  
2-8
[8]  
Gabay C, 2001, ARTHRITIS RHEUM-US, V44, P451, DOI 10.1002/1529-0131(200102)44:2<451::AID-ANR64>3.3.CO
[9]  
2-8
[10]   Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen-induced arthritis [J].
Goodfellow, RM ;
Williams, AS ;
Levin, JL ;
Williams, BD ;
Morgan, BP .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2000, 119 (01) :210-216